Conformational epitope on immunoglobulin light chain amyloid fibrils (AL amyloid fibril epitope)

The conformational epitope on immunoglobulin light chain (AL) amyloid fibrils is a unique structural motif that becomes accessible only when light chains misfold and aggregate into amyloid deposits. In systemic AL amyloidosis, monoclonal light chains produced by plasma cells form toxic oligomers and insoluble fibrils that deposit in organs, most critically the heart and kidneys, leading to progressive organ failure (Merlini et al., 2018). This neoepitope is absent in the native, correctly folded state of light chains, allowing for highly specific therapeutic targeting that spares healthy proteins. Therapeutic monoclonal antibodies, such as birtamimab (NEOD001) and anselamimab (CAEL-101), are engineered to bind this epitope to promote the clearance of amyloid through macrophage-mediated phagocytosis (Giedlin et al., 2016). Beyond clearing insoluble fibrils, these agents may also neutralize soluble toxic aggregates that contribute to acute organ dysfunction. This target is central to amyloid-clearing strategies, which complement traditional chemotherapy aimed at suppressing the underlying plasma cell clone (Edwards et al., 2021). Clinical trials targeting this epitope focus on improving survival and organ function in patients with high-risk AL amyloidosis. The specificity of this epitope minimizes off-target effects on functional, circulating immunoglobulins.

Other names

Cryptic epitope on AL fibrilsAL amyloid neoepitopeMisfolded light chain epitopeAmyloid-associated conformational epitope

Monoclonal antibodies bind to the conformational neoepitope on misfolded light chains and fibrils, triggering antibody-dependent cellular phagocytosis (ADCP) by macrophages and neutralizing soluble toxic oligomers (Giedlin et al., 2016; Edwards et al., 2021).